This is a very interesting time to be looking at this stock. Along with the rest of small cap stocks in the speculative space(ie Biotech et al.) it has gotten creamed in the market meltdown. The market cap is less than seventy million now, and was near four hundred million a few months ago.

But RVX is developing a drug that could revolutionize the treatment of atherosclerosis, and the value of that is hard to estimate. Their drug RVX 208, raises the level of HDL(Apo A 1 for those of you a bit more scientifically inclined) and the last compound to raise HDL in this way was shown to REDUCE the plaque in arteries otherwise known as atherosclerosis. Their pill is in early human testing, but so far has been shown safe and has exceeded expectations in it's efficacy. The benchmark was to raise HDL 8% and they have already shown their compound raises it 10% after only one week.

So talk to a scientific or medical friend, do some research, and have a look here. I personally think this is the most seriously undervalued biotech out there, virtually unknown because it is on the Toronto exchange. They are reportedly in advanced negotiations to partner the drug or sell the company, and either event should give the stock price a nice bump.

The only downside I'm personally concerned about is that unless they get a deal done in the next few months they will have to raise some cash. I believe they can do that, current financial realities notwithstanding, but would prefer them to have a non dilutive financing event.